New Cancer Treatment Model Using Anti-MCM2 Intrabody

2014 Fiscal Year Final Research Report

• Project/Area Number: 25860290
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Experimental pathology
• Research Institution: Tokyo Medical and Dental University
• Principal Investigator: ABE Shinya 東京医科歯科大学, 医歯(薬)学総合研究科, 助教 (70596725)
• Co-Investigator(Renkei-kenkyūsha): KITAGAWA Masanobu 東京医科歯科大学, 大学院医歯学総合研究科, 教授 (10177834)
• Project Period (FY): 2013-04-01 – 2015-03-31
• Keywords: MCM2 / アポトーシス / 治療モデル / 細胞内抗体 / ファージディスプレイ

Outline of Final Research Achievements

In a previous study, we showed that Friend leukemia virus (FLV) envelope protein gp70 bound MCM2, impaired its nuclear translocation, and enhanced DNA-damage-induced apoptosis in hematopoietic cells when the cells expressed high levels of MCM2.
Here, we aimed to create a new cancer treatment model by interrupting the nuclear transition of MCM2 using the anti-MCM2 intrabody instead of gp70. We first conducted separation of anti-MCM2 antibody by phage display method, and were successful to separate specific antibody against MCM2. We, furthermore, confirmed that, in vitro and in vivo, this antibody connects with MCM2 in the cell and fortifies apoptosis caused by the anti-cancer drug. It is thought that, by furthering the study, this treatment by anti-MCM2 intrabody would be a model for new tumor treatments.

Free Research Field

実験病理